Home > Search Results: Hernandez, Ainhoa
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 5 records found  Search took 0.01 seconds. 
1.
6 p, 870.5 KB Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C / Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. [...]
2023 - 10.3389/fonc.2023.1239000
Frontiers in Oncology, Vol. 13 (october 2023)  
Detailed record - Creative Commons
2.
17 p, 1.4 MB Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer-COVID Lung Vaccine Study / Hernandez, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Boigues Pons, Marc (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Notario, Lucia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pous, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Torres, Pere (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Benitez, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rodriguez, Marina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fuster, Daniel (Universitat Autònoma de Barcelona. Departament de Medicina) ; Moran, Teresa (Universitat Autònoma de Barcelona. Departament de Medicina)
During the SARS-CoV-2 pandemic, lung cancer patients have been considered an especially vulnerable population and have been prioritized for vaccination. However, several aspects (degree of immunity, potential interaction with active anticancer therapy, safety, and tolerability of the vaccines) remained unclear. [...]
2022 - 10.3390/cancers15010137
Cancers, Vol. 15, Num. 1 (January 2022) , art. 137  
Detailed record - Creative Commons
3.
12 p, 3.1 MB Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer / Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martinez-Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pros, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic rearrangements, including gene fusions and gene amplification, involving and activating receptor tyrosine kinases (RTKs) are recurrent in solid tumors, particularly in non-small cell lung cancer. [...]
2022 - 10.1016/j.ctrv.2022.102430
Cancer Treatment Reviews, Vol. 109 (september 2022) , p. 102430  
Detailed record - Creative Commons
4.
11 p, 1.7 MB In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma / Hernández, Ainhoa (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Muñoz-Mármol, Ana Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Esteve-Codina, Anna (Universitat Pompeu Fabra) ; Alameda, Francesc (Institut Hospital del Mar d'Investigacions Mèdiques) ; Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pineda, Estela (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Arpí Lluciá, Oriol (Institut Hospital del Mar d'Investigacions Mèdiques) ; Martinez-García, Maria (Hospital del Mar (Barcelona, Catalunya)) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gut, Marta (Universitat Pompeu Fabra) ; Del Barco Berrón, Sonia (Hospital Universitari de Girona Doctor Josep Trueta) ; Gallego Rubio, Oscar (Institut d'Investigació Biomèdica Sant Pau) ; Dabad, Marc (Universitat Pompeu Fabra) ; Mesia, Carlos (Institut d'Investigació Biomèdica de Bellvitge) ; Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ; Domènech Viñolas, Marta (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Vidal, Noemí (Hospital Universitari de Bellvitge) ; Aldecoa, Iban (Universitat de Barcelona) ; de la Iglesia, Nuria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Balañá, Carmen (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Universitat Autònoma de Barcelona
RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in tumor samples from 139 newly diagnosed glioblastoma patients to identify in-frame fusions with predictable oncogenic potential. [...]
2022 - 10.1038/s41598-022-18608-8
Scientific reports, Vol. 12 Núm. 1 (december 2022) , p. 14439  
Detailed record - Creative Commons
5.
17 p, 936.9 KB Hypoxia : the cornerstone of glioblastoma / Domènech Viñolas, Marta (Institut Català d'Oncologia) ; Hernández, Ainhoa (Institut Català d'Oncologia) ; Plaja, Andrea (Institut Català d'Oncologia) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Balañá, Carmen (Institut Català d'Oncologia)
Glioblastoma is the most aggressive form of brain tumor in adults and is characterized by the presence of hypervascularization and necrosis, both caused by a hypoxic microenvironment. In this review, we highlight that hypoxia-induced factor 1 (HIF-1), the main factor activated by hypoxia, is an important driver of tumor progression in GB patients. [...]
2021 - 10.3390/ijms222212608
International journal of molecular sciences, Vol. 22 Núm. 22 (november 2021) , p. 12608  
Detailed record - Creative Commons

See also: similar author names
6 Hernandez, A.
1 Hernandez, A.M.
1 Hernandez, Adrian V.
3 Hernandez, Alba
7 Hernandez, Albert
1 Hernandez, Alberto
2 Hernandez, Alejandro
1 Hernandez, Alina
1 Hernandez, Ana L.
1 Hernandez, Antonio
1 Hernàndez, Adriana
1 Hernàndez, Adrià
6 Hernández, A.
1 Hernández, A.F.
1 Hernández, A.I.P.
1 Hernández, A.L.
1 Hernández, A.M.
1 Hernández, A.P.R.
2 Hernández, Adalberto Magdaleno
1 Hernández, Agustina.
5 Hernández, Ainhoa
3 Hernández, Alba
7 Hernández, Albert
2 Hernández, Alejandro
1 Hernández, Alfredo I.
1 Hernández, Alicia
1 Hernández, Alma Johanna
1 Hernández, Almudena
1 Hernández, Ana
1 Hernández, Andrés
1 Hernández, Anjara
2 Hernández, Antonio M.
1 Hernández, Armand
1 Hernández, Astrid
1 Hernández, Ángel Alonso
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with